A UF research team has been approved for a five-year, $11.9 million award to compare the benefits and harms of proton therapy to standard radiation therapy when treating prostate cancer. Nancy Mendenhall, M.D., medical director of the UF Health Proton Therapy Institute, leads the team that received funding from the Patient-Centered Outcomes Research Institute for a large-scale clinical study on prostate cancer, which is the most common non-skin cancer afflicting men in the United States, according to the American Cancer Society.